VaxThera, Seguros SURA Colombia’s new biotechnological investment, seals an alliance for strengthening vaccine development both in Colombia and the rest of Latin America

  • VaxThera joins forces with the Indian company Gennova Biopharmaceuticals Ltd. to produce vaccines using mRNA technology as well as other biologicals, these to be made available throughout the country.
  • This is the beginning of a long-term relationship that seeks to strengthen our nation´s capacities to fill and finish and transfer technology for researching, developing and producing vaccines and biologicals on a local level.

COVID-19 made it clear that the world must prepare for future pandemics, which is why it is so necessary to deploy all our  human, technological and logistical capabilities in order to protect our population from emerging diseases and other epidemics that will surely continue to affect the region.

In the midst of this situation, VaxThera, a Colombian biotechnology company thanks to an investment made by Seguros SURA Colombia, a subsidiary of Suramericana, has been consolidating its undertaking for helping to extend the country´s technological independence for producing vaccines and biologicals and in so doing help to extend health security throughout Latin America.

In order to achieve this goal, VaxThera has formalized its intention to enter into a long-term alliance with Gennova Biopharmaceuticals Ltd., a biotechnology company based in Pune, India, engaged in developing, producing and marketing of biologics for treating life-threatening diseases.

"One of the great advances that the pandemic has left us with was the accelerated development of vaccines so as to provide timely care to the population, one of these being the mRNA technology. With this agreement, Colombia and the rest of the region shall have access to state-of-the-art vaccines for addressing both this and other future pandemics. This is an opportunity for further developing science and technology in Colombia”, pointed out Jorge Emilio Osorio, CEO of VaxThera.

The alliance between both companies will initially enable the commercialization of Gennova products in by Colombia and the region on the part of VaxThera, as well as joining efforts to strengthen experience, update technologies and manage resources for the field of science in Colombia. 

"This agreement is of great importance to us, as it gives us the opportunity to offer our state-of-the-art vaccines and biologics to a market such as Latin America. We know that, together with VaxThera, we shall be able to reach out to many people who need excellent quality products”, stated Sanjay Singh, CEO of Gennova.

This alliance between VaxThera and Gennova shall advance the Government's purpose of creating the country´s own capabilities for producing vaccines with the highest quality standards and based on rigorous studies.

About Vax Thera
VaxThera is a science-focused Colombian company dedicated to the research and development of biologicals for the entire world. The Company seeks to create greater health care independence through research, development and innovation in biotechnology and health. VaxThera came into being thanks to the combined efforts of Seguros SURA and world-renowned researchers in the field of biotechnology and human health. The Company is led by a team of staff with more than 30 years of experience in researching and developing biologicals. For more information visit:

About Gennova
Gennova Biopharmaceuticals Ltd., based in Pune, India, is a biotechnological company dedicated to researching, developing, producing and commercializing biosimilars. For more information visit: